Dutasteride works by inhibiting both Type 1 and Type 2 isoforms of the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT). By blocking this conversion, dutasteride reduces serum DHT levels by up to 94%, shrinking the prostate gland in BPH patients and halting or reversing miniaturization of hair follicles in androgenetic alopecia, which is an off-label use.
The 5-Alpha Reductase Enzyme
5-alpha reductase is an enzyme found throughout the body that converts testosterone, the primary male sex hormone, into dihydrotestosterone (DHT). DHT is a more potent androgen that binds to androgen receptors with greater affinity than testosterone. While DHT plays important roles during male fetal development and puberty, in adulthood it is the primary driver of both prostate growth and androgenetic hair loss.
There are three known isoforms of 5-alpha reductase:
- Type 1: Found primarily in the skin (including scalp), liver, and sebaceous glands
- Type 2: Found primarily in the prostate, seminal vesicles, epididymis, and hair follicles
- Type 3: Found in various tissues; its clinical significance is still being studied
How Dutasteride Inhibits 5-Alpha Reductase
Dutasteride is a competitive and specific inhibitor of both Type 1 and Type 2 5-alpha reductase isoforms. It forms a stable enzyme-inhibitor complex, effectively rendering the enzyme inactive. This dual inhibition is what distinguishes dutasteride from finasteride, which inhibits only the Type 2 isoform.
The result is a more complete suppression of DHT production:
| Metric | Dutasteride | Finasteride |
|---|---|---|
| Isoforms inhibited | Type 1 + Type 2 | Type 2 only |
| Serum DHT reduction | Up to 94% | About 65% at 1 mg, about 70% at 5 mg |
| Time to maximum suppression | 1-2 weeks | 1-2 weeks |
Mechanism in BPH
In benign prostatic hyperplasia, DHT stimulates the growth of prostate epithelial and stromal cells, leading to prostate enlargement. By reducing intraprostatic DHT levels, dutasteride causes apoptosis (programmed cell death) of prostate cells, leading to a measurable reduction in prostate volume, typically 20-25% over 6-12 months. This reduction relieves urinary symptoms including weak stream, frequency, urgency, and nocturia. Read more about dutasteride for BPH.
Mechanism in Hair Loss
In androgenetic alopecia, DHT binds to androgen receptors in genetically susceptible hair follicles, triggering a process called follicular miniaturization. Over successive hair growth cycles, affected follicles produce thinner, shorter, and less pigmented hairs until they eventually stop producing visible hair entirely.
By reducing both serum and scalp DHT levels, dutasteride slows or halts follicular miniaturization and, in many cases, reverses it, allowing miniaturized follicles to recover and produce thicker, longer terminal hairs. The greater DHT suppression achieved by dutasteride (about 94%, against about 65% for finasteride 1 mg and about 70% for finasteride 5 mg) is the usual explanation for the larger hair-count increase recorded in head-to-head trials. In a 24-week randomised comparison, dutasteride 0.5 mg daily raised total hair count per cm² from 223 to 246, while finasteride 1 mg daily moved it from 227 to 231 (Shanshanwal and Dhurat, Indian J Dermatol Venereol Leprol 2017). Read more about dutasteride for hair loss.
Pharmacokinetics
Dutasteride has unique pharmacokinetic properties that affect how it is used clinically:
- Absorption: Approximately 60% bioavailability after oral administration. Absorption is not significantly affected by food.
- Distribution: Highly protein-bound (99.0% to albumin, 96.6% to alpha-1 acid glycoprotein). Large volume of distribution.
- Metabolism: Extensively metabolized by the liver, primarily by CYP3A4 and CYP3A5 enzymes.
- Elimination: Terminal half-life of approximately 5 weeks at steady state. Excreted primarily in feces (~40% as metabolites; ~5% unchanged).
- Steady state: Serum concentrations reach 65% of steady state after 1 month and approximately 90% after 3 months (FDA label section 12.3).
The long half-life has practical implications: effects persist for months after discontinuation, twice-weekly dosing may be effective, and blood donation should be avoided for 6 months after the last dose.
Sources
- FDA. Avodart prescribing information (Clinical Pharmacology section). accessdata.fda.gov
- FDA. PROPECIA (finasteride) prescribing information. dailymed.nlm.nih.gov
- FDA. PROSCAR (finasteride) prescribing information. dailymed.nlm.nih.gov
- Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004 May;89(5):2179-84. PMID 15126539
- NCBI StatPearls. Dutasteride. ncbi.nlm.nih.gov